Table 1 Comparisons of baseline characteristics between the SH group and control group in the low- to moderate-risk (n = 508), and high- to very high-risk (n = 446) MRS group, respectively

Age, years

67.9 (8.8)

66.9 (9.3)

0.2072^a

71.3 (10.5)

70.6 (10.1)

0.4604^a

Male, %

68 (26.1)

61 (24.7)

0.8031^b

54 (24.4)

58 (25.8)

0.8275^b

DM, n (%)

77 (29.5)

76 (30.8)

0.8302^b

129 (58.4)

133 (59.1)

0.9501^b

CHF, n (%)

21 (8.0)

17 (6.9)

0.7418^b

108 (48.9)

102 (45.3)

0.5137^b

CAD, n (%)

237 (90.8)

220 (89.1)

0.6150^b

209 (94.6)

210 (93.3)

0.7271^b

AMI, n (%)

36 (13.8)

32 (13.0)

0.8833^b

38 (17.2)

46 (20.4)

0.4493^b

Hypertension, n (%)

230 (88.1)

217 (87.9)

1.0000^b

193 (87.3)

182 (80.9)

0.0837^b

Scr, mg/dL

1.4 (0.2)

1.4 (0.2)

0.6103^a

1.8 (0.5)

1.8 (0.5)

0.7444^a

eGFR, mL/min/1.73 m²

51.1 (6.5)

51.2 (7.3)

0.9605^a

40.0 (10.6)

40.0 (14.9)

0.9782^a

BUN, mmol/L

8.0 (2.5)

7.5 (2.1)

0.0191^a

10.6 (4.4)

10.5 (4.2)

0.8155^a

CysC, mg/L

1.4 (0.4)

1.4 (0.4)

0.9416^a

1.8 (0.5)

1.9 (0.6)

0.6082^a

CRP, mg/L

16.6 (25.0)

27.6 (61.5)

0.3102^a

17.1 (21.9)

24.7 (37.4)

0.2438^a

BNP, pg/ml

264.2 (442.1)

261.8 (428.2)

0.9856^a

399.2 (554.1)

478.4 (613.8)

0.5935^a

LVEF, %

58.5 (9.8)

58.8 (11.6)

0.8181^a

55.6 (12.5)

53.8 (13.1)

0.1731^a

Anemia, n (%)

97 (37.2)

78 (31.6)

0.2184^b

154 (69.7)

155 (68.9)

0.9369^b

IABP, n (%)

0 (0.0)

0 (0.0)

NA

2 (0.9)

5 (2.2)

0.4605^b

Non-PCI, %

149 (57.1)

111 (44.9)

0.0081^b

111 (50.2)

105 (46.7)

0.5110^b

CMV, mL

102.9 (67.3)

113.6 (65.1)

0.0706^b

126.2 (81.5)

122.7 (68.6)

0.6219^b

Periprocedural intravenous hydration volume, mL

1200.4 (619.1)

1601.7 (776.7)

 < 0.0001^a

1072.4 (569.0)

1412.5 (674.1)

 < 0.0001^a

Periprocedural urine volume, mL

1763.4 (1148.5)

1991.4 (1155.6)

0.0965^a

1584.4 (962.9)

2135.0 (3803.5)

0.1021^a